Coya Therapeutics, Inc. Financials
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
Coya Therapeutics, Inc. has an operating margin of -485.4%, meaning the company retains $-485 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is down from -131.7% the prior year.
Coya Therapeutics, Inc.'s revenue declined 40.8% year-over-year, from $6.0M to $3.6M. This contraction results in a growth score of 0/100.
Coya Therapeutics, Inc. carries a low D/E ratio of 0.12, meaning only $0.12 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 11.59, Coya Therapeutics, Inc. holds $11.59 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
Coya Therapeutics, Inc. passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.
For every $1 of reported earnings, Coya Therapeutics, Inc. generates $0.69 in operating cash flow (-$10.3M OCF vs -$14.9M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
This page shows Coya Therapeutics, Inc. (COYA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
Coya Therapeutics, Inc. generated $3.6M in revenue in fiscal year 2024. This represents a decrease of 40.8% from the prior year.
Coya Therapeutics, Inc.'s EBITDA was -$17.2M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 118.7% from the prior year.
Coya Therapeutics, Inc. reported -$14.9M in net income in fiscal year 2024. This represents a decrease of 86.3% from the prior year.
Coya Therapeutics, Inc. earned $-0.98 per diluted share (EPS) in fiscal year 2024. This represents a decrease of 24.1% from the prior year.
Coya Therapeutics, Inc. held $38.3M in cash against $0 in long-term debt as of fiscal year 2024.
Coya Therapeutics, Inc. had 17M shares outstanding in fiscal year 2024. This represents an increase of 16.0% from the prior year.
Coya Therapeutics, Inc.'s operating margin was -485.4% in fiscal year 2024, reflecting core business profitability. This is down 353.7 percentage points from the prior year.
Coya Therapeutics, Inc.'s net profit margin was -418.7% in fiscal year 2024, showing the share of revenue converted to profit. This is down 285.6 percentage points from the prior year.
Coya Therapeutics, Inc. invested $11.9M in research and development in fiscal year 2024. This represents an increase of 115.7% from the prior year.
COYA Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.6M+2078.4% | $164K-36.6% | $258K+13111.3% | $2K-99.9% | $3.4M+2600.5% | $127K-97.9% | $6.0M | $0 |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $2.9M-20.4% | $3.7M-29.7% | $5.2M+169.1% | $1.9M-57.6% | $4.6M+45.5% | $3.1M+95.0% | $1.6M+1.1% | $1.6M |
| SG&A Expenses | $2.6M-12.1% | $2.9M+7.2% | $2.7M+26.9% | $2.1M+2.4% | $2.1M-14.4% | $2.4M+2.6% | $2.4M+21.0% | $2.0M |
| Operating Income | -$2.4M+62.1% | -$6.4M+16.4% | -$7.7M-88.1% | -$4.1M-26.1% | -$3.2M+41.0% | -$5.5M-402.1% | $1.8M+150.9% | -$3.6M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | $0 | N/A | N/A | $0 | N/A | N/A | N/A |
| Net Income | -$2.1M+65.3% | -$6.1M+16.6% | -$7.3M-150.6% | -$2.9M-0.8% | -$2.9M+42.8% | -$5.1M-499.1% | $1.3M+137.0% | -$3.4M |
| EPS (Diluted) | $-0.13+63.9% | $-0.36+18.2% | $-0.44-144.4% | $-0.18+5.3% | $-0.19+45.7% | $-0.35-350.0% | $0.14+141.2% | $-0.34 |
COYA Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $32.0M-4.2% | $33.5M-12.9% | $38.4M-13.4% | $44.3M+11.0% | $39.9M+6.8% | $37.4M-9.4% | $41.3M+246.9% | $11.9M |
| Current Assets | $32.0M-4.2% | $33.4M-12.9% | $38.4M-13.4% | $44.3M+11.1% | $39.9M+6.8% | $37.3M-9.4% | $41.2M+248.5% | $11.8M |
| Cash & Equivalents | $28.1M-5.5% | $29.8M-16.2% | $35.5M-7.3% | $38.3M+4.8% | $36.6M+1.6% | $36.0M+10.3% | $32.6M+199.7% | $10.9M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $4.8M-7.5% | $5.1M+2.1% | $5.0M+5.6% | $4.8M+1.9% | $4.7M-6.4% | $5.0M-11.1% | $5.6M+211.4% | $1.8M |
| Current Liabilities | $3.7M-18.5% | $4.5M+3.7% | $4.3M+13.5% | $3.8M0.0% | $3.8M-11.4% | $4.3M-14.5% | $5.1M+179.6% | $1.8M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $27.3M-3.6% | $28.3M-15.2% | $33.4M-15.7% | $39.6M+12.3% | $35.3M+8.8% | $32.4M-9.1% | $35.6M+253.2% | $10.1M |
| Retained Earnings | -$56.3M-3.9% | -$54.1M-12.7% | -$48.0M-17.9% | -$40.7M-20.5% | -$33.8M-9.4% | -$30.9M-19.5% | -$25.9M+4.7% | -$27.1M |
COYA Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$1.1M+80.4% | -$5.8M-104.1% | -$2.8M-17.4% | -$2.4M+47.2% | -$4.6M-312.7% | $2.1M+195.8% | -$2.2M-1.1% | -$2.2M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | N/A | N/A | N/A | $0 | $0+100.0% | -$25K+87.1% | -$193K | $0 |
| Financing Cash Flow | $19K | $0-100.0% | $19K-99.8% | $9.7M+88.2% | $5.1M+314.7% | $1.2M-94.9% | $24.2M | $0 |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
COYA Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -68.3%+3852.2pp | -3920.5%-943.6pp | -2976.9%+206054.6pp | -209031.5%-208937.0pp | -94.5%+4228.4pp | -4322.8%-4353.1pp | 30.2% | N/A |
| Net Margin | -59.4%+3665.8pp | -3725.2%-891.8pp | -2833.3%+146540.4pp | -149373.8%-149289.3pp | -84.4%+3898.5pp | -3983.0%-4004.1pp | 21.1% | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | 3.5% | N/A |
| Return on Assets | -6.6%+11.6pp | -18.2%+0.8pp | -19.0%-12.5pp | -6.6%+0.7pp | -7.2%+6.3pp | -13.5%-16.6pp | 3.1%+31.8pp | -28.8% |
| Current Ratio | 8.73+1.3 | 7.43-1.4 | 8.84-2.7 | 11.59+1.2 | 10.43+1.8 | 8.64+0.5 | 8.15+1.6 | 6.54 |
| Debt-to-Equity | 0.170.0 | 0.18+0.0 | 0.15+0.0 | 0.12-0.0 | 0.13-0.0 | 0.150.0 | 0.16-0.0 | 0.18 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
What is Coya Therapeutics, Inc.'s annual revenue?
Coya Therapeutics, Inc. (COYA) reported $3.6M in total revenue for fiscal year 2024. This represents a -40.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Coya Therapeutics, Inc.'s revenue growing?
Coya Therapeutics, Inc. (COYA) revenue declined by 40.8% year-over-year, from $6.0M to $3.6M in fiscal year 2024.
Is Coya Therapeutics, Inc. profitable?
No, Coya Therapeutics, Inc. (COYA) reported a net income of -$14.9M in fiscal year 2024, with a net profit margin of -418.7%.
What is Coya Therapeutics, Inc.'s earnings per share (EPS)?
Coya Therapeutics, Inc. (COYA) reported diluted earnings per share of $-0.98 for fiscal year 2024. This represents a -24.1% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Coya Therapeutics, Inc.'s EBITDA?
Coya Therapeutics, Inc. (COYA) had EBITDA of -$17.2M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Coya Therapeutics, Inc.'s operating margin?
Coya Therapeutics, Inc. (COYA) had an operating margin of -485.4% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Coya Therapeutics, Inc.'s net profit margin?
Coya Therapeutics, Inc. (COYA) had a net profit margin of -418.7% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Coya Therapeutics, Inc.'s operating cash flow?
Coya Therapeutics, Inc. (COYA) generated -$10.3M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Coya Therapeutics, Inc.'s total assets?
Coya Therapeutics, Inc. (COYA) had $44.3M in total assets as of fiscal year 2024, including both current and long-term assets.
How much does Coya Therapeutics, Inc. spend on research and development?
Coya Therapeutics, Inc. (COYA) invested $11.9M in research and development during fiscal year 2024.
How many shares does Coya Therapeutics, Inc. have outstanding?
Coya Therapeutics, Inc. (COYA) had 17M shares outstanding as of fiscal year 2024.
What is Coya Therapeutics, Inc.'s current ratio?
Coya Therapeutics, Inc. (COYA) had a current ratio of 11.59 as of fiscal year 2024, which is generally considered healthy.
What is Coya Therapeutics, Inc.'s debt-to-equity ratio?
Coya Therapeutics, Inc. (COYA) had a debt-to-equity ratio of 0.12 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Coya Therapeutics, Inc.'s return on assets (ROA)?
Coya Therapeutics, Inc. (COYA) had a return on assets of -33.6% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Coya Therapeutics, Inc.'s cash runway?
Based on fiscal year 2024 data, Coya Therapeutics, Inc. (COYA) had $38.3M in cash against an annual operating cash burn of $10.3M. This gives an estimated cash runway of approximately 45 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Coya Therapeutics, Inc.'s Piotroski F-Score?
Coya Therapeutics, Inc. (COYA) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Coya Therapeutics, Inc.'s earnings high quality?
Coya Therapeutics, Inc. (COYA) has an earnings quality ratio of 0.69x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Coya Therapeutics, Inc.?
Coya Therapeutics, Inc. (COYA) scores 50 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.